Key result
Prehospital UFH is linked to ~49% higher odds of preprocedural TIMI 2-3 flow versus in-hospital UFH.
Why the study?
In STEMI, myocardial loss continues until coronary reperfusion, but whether prehospital unfractionated heparin improves preprocedural infarct-related artery patency and clinical outcomes remained to be evaluated.
Does prehospital unfractionated heparin improve preprocedural coronary patency and clinical outcomes in patients with STEMI undergoing primary PCI?
Meta-Analysis (n=10,954)
Does prehospital unfractionated heparin improve preprocedural coronary patency and clinical outcomes in patients with STEMI undergoing primary PCI?
Prehospital administration of unfractionated heparin in STEMI patients undergoing primary PCI improves preprocedural coronary patency and may reduce short-term mortality without increasing major bleeding.
Answers are grounded in this paper and cite their sources.
Supports prehospital UFH consideration in STEMI; extends mixed evidence but requires RCT confirmation.
Background and importance In patients with ST-segment elevation myocardial infarction (STEMI), myocardial loss continues until coronary reperfusion is achieved. Objective To evaluate whether prehospital administration of unfractionated heparin (UFH) improves preprocedural infarct-related artery patency and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI). Design Systematic review and meta-analysis. Electronic databases (PubMed, EMBASE, CENTRAL, and Web of Science) and clinical trial registries were systematically searched through March 2026. Settings and participants Patients with STEMI scheduled for primary PCI across seven included studies (two randomized controlled trials and five observational studies), totaling 10 954 participants, with 78.1% male patients. Intervention or exposure Prehospital UFH administration compared with PCI-capable hospital UFH administration. Outcome measures and analysis Prespecified endpoints included pre- and postprocedural thrombolysis in myocardial infarction (TIMI) flow grade, 30-day mortality, a composite endpoint of 30-day or in-hospital mortality, and major bleeding events. Main results Prehospital UFH was associated with a significantly higher rate of preprocedural TIMI 2–3 flow compared with control [odds ratio (OR): 1.49, 95% confidence interval (CI): 1.28–1.74; P < 0.001). Prehospital UFH was not associated with a significant reduction in 30-day all-cause mortality (OR: 0.70, 95% CI: 0.44–1.13; P = 0.141; I 2 = 60.9%), although a significant reduction was observed for the composite endpoint of 30-day or in-hospital mortality across all seven studies (OR: 0.68, 95% CI: 0.49–0.95; P = 0.023). Prehospital UFH was not associated with a significantly increased risk of major bleeding (OR: 0.77, 95% CI: 0.57–1.05; P = 0.099; I 2 = 0%). Conclusion In patients with STEMI undergoing primary PCI, prehospital UFH was associated with improved preprocedural coronary patency without an apparent increase in major bleeding. However, no statistically significant reduction was observed in 30-day mortality. Large-scale randomized controlled trials adequately powered for clinical endpoints are needed to establish the role of prehospital UFH in contemporary STEMI care.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a meta-analysis in ST-segment elevation myocardial infarction (STEMI) (n=10,954). Prehospital unfractionated heparin (UFH) vs. PCI-capable hospital UFH administration was evaluated on Preprocedural TIMI 2-3 flow (OR 1.49, 95% CI 1.28-1.74, p=<0.001). Prehospital unfractionated heparin was associated with a higher rate of preprocedural TIMI 2-3 flow compared with in-hospital administration.
Synapse has enriched 10 related papers. Consider them for comparative context: